New therapeutic approach for the treatment for staphylococcal bacteremia and sepsis
- Authors: Beloborodov V.B1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education Studies
- Issue: Vol 19, No 5 (2014)
- Pages: 19-25
- Section: Articles
- URL: https://bakhtiniada.ru/1560-9529/article/view/40824
- DOI: https://doi.org/10.17816/EID40824
- ID: 40824
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V. B Beloborodov
Russian Medical Academy of Postgraduate Education Studies
Email: vb_beloborodov@mail.ru
доктор мед. наук, проф. каф. инфекционных болезней 2/1, Barrikadnaya Str. , Moscow, Russian Federation, 125993
References
- Shorr A.F., Tabak Y.P., Killian A.D., Gupta V., Liu L.Z., Kollef M.H. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006; 34: 2588-95.
- UK Health Protection Agency. Voluntary Reporting of Staphylococcus aureus bacteraemia in England, Wales, and Northern Ireland January-December 2008. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560519595 (accessed Nov 30, 2010).
- Wyllie D.H., Crook D.W., Peto T.E. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 19972003: cohort study. Br. Med. J. 2006; 333: 281.
- Грувер К.П., Белобородов В.Б. Клиническое значение бактериемии у больных сепсисом. Клиническая микробиология и антибактериальная химиотерапия. 2011; 13(1): 90-7.
- Liu C., Bayer A., Cosgrove S.E. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin. Infect. Dis. 2011; 52: 1-38.
- Naber C.K., Baddour L.M., Giamarellos-Bourboulis E.J. et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin. Infect. Dis. 2009; 48 (Suppl. 4): S. 260.
- Khatib R., Johnson L.B., Fakih M.G. et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand. J. Infect. Dis. 2006; 38: 7-14.
- Wilson R., Hamburger M. Fifteen years’ experience with Staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am. J. Med. 1957; 22: 437-57.
- Fernandez Guerrero M.L., Gonzalez Lopez J.J., Goyenechea A., Fraile J., de Gorgolas M. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore). 2009; 88: 1-22.
- Chang F.Y., Mac Donald B.B., Peacock J.E. Jr. et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003; 82: 322-32.
- Van Hal S.J., Mathur G., Kelly J., Aronis C., Cranney G.B., Jones P.D. The role of transthoracic echocardiography in excluding left sided infective endocarditis in Staphylococcus aureus bacteraemia. J. Infect. 2005; 51: 218-21.
- Evangelista A., Gonzalez-Alujas M.T. Echocardiography in infective endocarditis. Heart. 2004; 90: 614-7.
- Fortun J., Navas E., Martinez-Beltran J., et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin. Infect. Dis. 2001; 33: 120-5.
- Khatib R., Johnson L.B., Sharma M., Fakih M.G., Ganga R., Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand. J. Infect. Dis. 2009; 41: 4-9.
- Lodise T.P. Jr., McKinnon P.S., Levine D.P., Rybak M.J. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 2007; 51: 3731-3.
- Appelbaum P.C. Reduced glycopeptide susceptibility inmethicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents. 2007; 30: 398-408.
- Rybak M.J., Leonard S.N., Rossi K.L., Cheung C.M., Sader H.S., Jones R.N. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 2008; 46: 2950-4.
- Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008; 52: 3315-20.
- Chambers H.F., Mills J., Drake T.A., Sande M.A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev. Infect. Dis. 1984; 6 (Suppl. 4): S870-4.
- Nannini E.C., Stryjewski M.E., Singh K.V. et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009; 53: 3437-41.
- Fujii R. Experience with cefotaxime in infections caused by Gram-positive pathogens, especially Staphylococcus aureus. Infection. 1985; 13 (Suppl. 1): S9-13.
- Soriano E., Gatell J.M., Aguado J.M. et al. Ceftriaxone monotherapy for severe bacteremic infections. Chemotherapy. 1989; 35 (Suppl. 2): 27-32.
- Rahal J.J.Jr., Chan Y.K., Johnson G. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am. J. Med. 1986; 81: 43-52.
- Zeylemaker M.M., Jaspers C.A., van Kraaij M.G., Visser M.R., Hoepelman I.M. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 380-4.
- Malanoski G.J., Samore M.H., Pefanis A., Karchmer A.W. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch. Intern. Med. 1995; 155: 1161-66.
- Ghanem G.A., Boktour M., Warneke C. et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore). 2007; 86: 54-60.
- Torres-Tortosa M., de Cueto M., Vergara A. et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 1994; 13: 559-64.
- Falagas M.E., Matthaiou D.K., Bliziotis I.A. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J. Antimicrob. Chemother. 2006; 57: 639-47.
- Cosgrove S.E., Vigliani G.A., Fowler V.G. Jr. et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 2009; 48: 713-21.
- Ruotsalainen E., Jarvinen A., Koivula I. et al. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J. Intern. Med. 2006; 259: 179-90.
- Gransden W.R., Eykyn S.J., Phillips I. Staphylococcus aureus bacteraemia: 400 episodes in St Thomas’s Hospital. Br. Med. J. 1984; 288: 300-03.
- Huang Y.T., Hsiao C.H., Liao C.H., Lee C.W., Hsueh P.R. Bacteremia and infective endocarditis caused by a nondaptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J. Clin. Microbiol. 2008; 46: 1132-36.
- Howden B.P., Ward P.B., Charles P.G. et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004; 38: 521-8.
- Whitby M. Fusidic acid in septicaemia and endocarditis. Int. J. Antimicrob. Agents. 1999; 12 (Suppl. 2): S17-22.
- Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 2005; 56: 923-9.
- Falagas M.E., Siempos I.I., Vardakas K.Z. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet. Infect. Dis. 2008; 8: 53-66.
- Falagas M.E., Manta K.G., Ntziora F., Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. 2006; 58: 273-80.
- Wilcox M.H., Tack K.J., Bouza E. et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin. Infect. Dis. 2009; 48: 203-12.
- Jang H.C., Kim S.H., Kim K.H. et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin. Infect. Dis. 2009; 49: 395-401.
- Fowler V.G.Jr., Boucher H.W., Corey G.R. et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 2006; 355: 653-65.
- Sakoulas G., Brown J., Lamp K.C., Friedrich L.V., Lindfield K.C. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin. Ther. 2009; 31: 1936-45.
- Falagas M.E., Giannopoulou K.P., Ntziora F., Vardakas K.Z. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J. Antimicrob. Chemother. 2007; 60: 7-19.
- Falagas M.E., Giannopoulou K.P., Ntziora F., Papagelopoulos P.J. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents. 2007; 30: 202-9.
- Sharma M., Riederer K., Chase P., Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 433-7.
- Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin. Microbiol. Infect. 2009; 15 (Suppl. 6): 11-6.
- Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R.C.Jr., Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 2006; 50: 1581-5.
- Rose W.E., Leonard S.N., Sakoulas G. et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2008; 52: 831-6.
- Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006; 50: 1079-82.
- Sader H.S., Fritsche T.R., Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 2006; 50: 2330-6.
- Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009; 43: 1211-9.
- Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 2007; 60: 334-40.
- Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 2006; 50: 3245-49.
- Dohmen P. et al. 22th (2012) European Congressof Clinical Microbiology and Infectious Diseases. Poster; 1844.
- Dohmen P. et al. 22th (2012) European Congressof Clinical Microbiology and Infectious Diseases. Poster; 1845.
Supplementary files
